Éragny-sur-Oise, France-based medical technology company Safe Orthopaedics announced the construction of its innovation and industrial production center and of a new integrated production unit in Fleurieux-sur-l’Arbresle (Rhône, France).
Safe Orthopaedics Breaks Ground on Expansion
1 min read Premium comments
Secondary#lcimedical#safeorthopaedics
Safe Orthopaedics develops and manufactures ready-to-use spine implants and instrument kits for orthopedic surgeons. The kits are delivered sterile and intended for single use. These technologies enable a “minimally invasive approach” and reduce “the risk of cross contamination and infection.”
In July 2020, Safe Orthopaedics acquired LCI Medical. LCI Medical manufactures surgical medical devices. Safe Orthopaedics can now utilize its knowledge and expertise to expand beyond orthopedics.
The expansion includes multiple phases. The first phase of the project will extend existing buildings to expand medical device production. This will support Safe Orthopaedics sales efforts. It will also enable the company to offer LCI Medical customers “new industrial services.”
The foundation stone ceremony was held earlier this month at LCI Medical. The first phase includes three new clean rooms for the innovation center of Safe Orthopaedics. The innovation center will be dedicated to creating new spinal orthopedic technologies. It is anticipated that the first phase will be completed in summer 2021 and will expand the workforce to 30 people.
In the press release, Safe Orthopaedics Chief Executive Officer and LCI Medical President Pierre Dumouchel stated, “These new industrial facilities will allow us to offer our customers a short cycle of innovation and to propose innovative logistical and commercial services. They will also allow us to promote ‘ready-to-use’ for new surgical indications and new markets, in partnership with manufacturers and/or through industrial subcontracting with a strong value added.”
Dumouchel continued, “In this year marked by a sanitary and economical crisis, Safe Orthopaedics chose not to deviate its trajectory and still aims, thanks to the integration of LCI Medical, a development that should allow it to achieve financial balance in early 2022.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.